MethylGene and Pharmion present favorable clinical data from combination MGCD0103/Vidaza® study

News | 12. 10. 2007

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (Nasdaq: PHRM) today announced maturing data from the Phase I/II study investigating the combined use of MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor, and Vidaza® (azacitidine for injection) in patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). A 53 percent response rate (n=19) was demonstrated at the 90 mg dose with a median time to response of less than two months. The overall results indicate a 36 percent response rate for patients evaluated at all doses (n=52 evaluable patients) in this Phase I/II study. The data were presented in an oral presentation today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.